In a meta-analysis of five RCTs (2317 patients with melanoma), BRAF/MEK inhibitors combined therapy was associated with a higher risk of LV dysfunction, particularly in younger patients (RR 26.50, 95% CI 3.58–196.10) [85]. Here, BRAF is linked to melanoma.